Patel Naimish 4
4 · CRISPR Therapeutics AG · Filed Jan 27, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) CMO Naimish Patel Buys 1,508 Shares
What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), made an open-market purchase of 1,508 common shares on April 3, 2025 at $32.96 per share, for a total value of about $49,704. This filing reports a purchase (code P), which is a direct acquisition rather than a sale or award.
Key Details
- Transaction date and price: April 3, 2025 — 1,508 shares at $32.96 each (~$49,703.68 / $49,704).
- Shares owned after transaction: Not disclosed in this Form 4.
- Footnote: The purchase was matchable under Section 16(b) to a subsequent sale of the same 1,508 shares on May 29, 2025 (a mandatory "sell to cover" tied to vested RSUs). Patel agreed to remit $4,493.84 to the issuer, representing the full short-swing profit. The sale was reported separately on a Form 4 filed May 30, 2025.
- Filing timeliness: The Form 4 was filed Jan 27, 2026 for a transaction dated Apr 3, 2025; this indicates a late filing.
Context
Purchases by executives are often watched by investors as potential signals of confidence, but motivations are not disclosed in the filing. The footnote clarifies this purchase was later matched to a required sell-to-cover related to vested RSUs and resulted in a Section 16(b) short-swing disposition remedy (payment of profit back to the company).
Insider Transaction Report
- Purchase
Common Shares
[F1]2025-04-03$32.96/sh+1,508$49,704→ 1,508 total
Footnotes (1)
- [F1]The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.